Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

PBS. 2020; 10(2): 45-54


Famotidine Improved Schizophrenia-Like Behaviors in Acute Ketamine Model of Schizophrenia in Rats

Gokhan Unal, Feyza Aricioglu.




Abstract

Objective: Schizophrenia is a devastating disorder with its positive (hallucination and delusion), negative (such as social withdrawal,
anhedonia), and cognitive (learning and attention deficits) symptoms. Although current antipsychotic drugs treat positive symptoms,
negative and cognitive symptoms have remained untreated. There is a limited number of studies showing the promising potential benefits of famotidine, an H2 receptor antagonist used for the treatment of peptic ulcer, in schizophrenic patients. In our previous study, it was showed that famotidine might improve schizophrenia-induced molecular deficits on Akt/GSK-3β/β-Catenin signaling pathway in SH-SY5Y cells and there is no translational study examining this effects of famotidine. Hence this study was designed to investigate the effects of famotidine on schizophrenia-like behavioral deficits in the acute ketamine model of schizophrenia in rats.
Methods: Male Sprague Dawley rats divided into the four groups as saline, famotidine, ketamine, ketamine+famotidine (n=8 per group). Prepulse inhibition (PPI) of acustic startle response, novel object recognition (NOR), fear conditioning (FC), and social interaction (SI) tests were performed to measure schizophrenia-like symptoms in rats. Ketamine (10 mg/kg) was administered 15 min before the PPI test or 15 mg/kg 30 min before the NOR, FC, and SI tests whereas famotidine (4.4 mg/kg) was administered 30 min before all behavioral tests.
Results: Ketamine decreased the PPI (%) at +8 dB (p

Key words: Ketamine, Famotidine, Schizophrenia, Prepulse Inhibition, Novel Object Recognition






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.